Press Release

NEUWAY Pharma GmbH signs License Agreement with University Zürich

Bonn, Zurich February 2015. University Zurich and NEUWAY Pharma GmbH, a German biotech start-up company, today announced that they have entered into a license agreement. Under the terms of this agreement NEUWAY will develop its technology to treat a rare but frequently fatal neurological disease called progressive multifocal leucoencephalopathy (PML).

Researchers at University Zurich found that NEUWAY’s engineered protein capsules (EPCs) may be used in the treatment of PML. EPCs have already been applied by clinical researchers at the university hospital of Zurich and found to enhance the immune response against the disease causing agent.

„With NEUWAY’s EPCs we have a promising tool for the therapy of PML“, says Dr. Roland Martin, clinical researcher at university Zurich, „however further clinical studies will be needed to determine safety and efficacy of this treatment option“.

For NEUWAY, the license agreement opens an additional business field: „Our primary goal is the use of EPCs as drug delivery system. In preclinical studies we found that EPCs show a low or even no immunogenicity. The immune response however could be enhanced by modulators to use empty EPCs as vaccine also“, says Heiko Manninga, Managing Director at NEUWAY.
About NEUWAY Pharma

NEUWAY Pharma GmbH, Bonn, Germany, is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform. The company also intends to partner its drug delivery technology for other CNS indications.

About Zürich University

The University of Zurich (UZH) is a member of the League of European Research Universities and numbers among Europe’s most prestigious research institutions. UZH’s international standing is reflected in the many renowned academic distinctions conferred upon its members, including twelve Nobel Prizes. As Switzerland’s largest university, UZH has a current enrollment of over 26,000 students and offers the most comprehensive academic program in the country. Over 5,000 excellent members of staff teach and perform research at one of the University’s 150 departments, including over 500 professors. UZH also looks back on a rich history, having been founded in 1833 as Europe's first university to be established by a democratic political system.

Further information

NEUWAY Pharma GmbH:
Dr. Stephan Rapp, +49-(0)228-522198-0,
Press Contact:
Christine Kuhn, +49-(0)228-522198-0, kuhn@neuway.de
www.neuway.de